HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs
- PMID: 12596719
- DOI: 10.1089/08892220360473952
HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs
Abstract
Non-B HIV-1 samples collected in France between 1999 and 2001 were sequenced in the env, reverse transcriptase (RT), and protease genes (1) to characterize further the non-B strains circulating in the country, (2) to assess the importance of recombination, and (3) to describe the polymorphism of RT and protease genes and appreciate a possible impact on susceptibility to antiretroviral (ARV) drugs. The results show that, within a background of CRF02_AG predominance, there is a high genetic diversity of non-B isolates, including intersubtype recombinants. There is an extensive polymorphism of protease and RT genes compared with B consensus sequences; we have so far no data indicating that these non-B isolates may have reduced sensitivity to ARV drugs.
Similar articles
-
Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.AIDS Rev. 2003 Jan-Mar;5(1):25-35. AIDS Rev. 2003. PMID: 12875105 Review.
-
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. doi: 10.1128/AAC.49.7.2575-2582.2005. Antimicrob Agents Chemother. 2005. PMID: 15980322 Free PMC article. Review. No abstract available.
-
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21. J Antimicrob Chemother. 2010. PMID: 20965891
-
Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Côte d'Ivoire.J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):111-3. doi: 10.1097/00126334-200309010-00016. J Acquir Immune Defic Syndr. 2003. PMID: 14501802 No abstract available.
-
HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571. Antivir Ther. 2010. PMID: 20587857
Cited by
-
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.J Clin Microbiol. 2005 Aug;43(8):3860-8. doi: 10.1128/JCM.43.8.3860-3868.2005. J Clin Microbiol. 2005. PMID: 16081923 Free PMC article.
-
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.J Int AIDS Soc. 2010 Feb 3;13:4. doi: 10.1186/1758-2652-13-4. J Int AIDS Soc. 2010. PMID: 20205896 Free PMC article.
-
Transmitted drug resistance in nonsubtype B HIV-1 infection.HIV Ther. 2009 Sep 1;3(5):447-465. doi: 10.2217/hiv.09.30. HIV Ther. 2009. PMID: 20161523 Free PMC article.
-
Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.J Int AIDS Soc. 2014 Jul 4;17(1):18944. doi: 10.7448/IAS.17.1.18944. eCollection 2014. J Int AIDS Soc. 2014. PMID: 24998532 Free PMC article.
-
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.Antimicrob Agents Chemother. 2004 Aug;48(8):2993-8. doi: 10.1128/AAC.48.8.2993-2998.2004. Antimicrob Agents Chemother. 2004. PMID: 15273111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical